Northeastern University, the Barnett Institute, and Cambridge-based BioAnalytix have partnered to host the annual Advanced Biologic Development Summit to help define, catalyze, and advance translational research and industry-leading standards at the intersection of analytic technologies, data analysis, and biopharmaceutical development.
Founded in 1898, Northeastern is a global, experiential, research university built on a tradition of engagement with the world, creating a distinctive approach to education and research. The university offers a comprehensive range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools, and select advanced degrees at graduate campuses in Charlotte, North Carolina, Seattle, Silicon Valley, and Toronto.
The Barnett Institute is a center of excellence in the development and application of technologies for biopharmaceutical characterization and proteomics and systems biology, with missions to:
- Develop and apply new technologies for basic and clinical biological research;
- Develop and apply new technologies for characterization of protein therapeutics;
- Train students and visiting scientists for academic, industrial, and medical leadership;
- Collaborate actively with the industrial, regulatory, medical and communities.
The Institute was established in 1973 as a center for advanced interdisciplinary research in the chemical analysis sciences at Northeastern University, in the educational hub of Boston, Massachusetts. It is housed in the Department of Chemistry & Chemical Biology in the College of Science at Northeastern.
BioAnalytix is a pharmaceutically oriented spin-out from the Barnett Institute of Chemical and Biological Analysis at Northeastern University. Founded in 2012 by thought leaders in biologic drug development, regulatory strategy, and advanced analytics, BioAnalytix works with leading pharmaceutical companies to develop and apply advanced analytic technologies, methods and data in enabling, improving and accelerating biologic therapeutics from development through market.